Compare · MLYS vs NVO
MLYS vs NVO
Side-by-side comparison of Mineralys Therapeutics Inc. (MLYS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLYS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.34B, about 94.5x MLYS ($2.07B).
- Over the past year, MLYS is up 60.0% and NVO is down 39.7% - MLYS leads by 99.7 points.
- MLYS has been more active in the news (14 items in the past 4 weeks vs 11 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for MLYS).
- Company
- Mineralys Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $25.00-0.16%
- $43.74+4.13%
- Market cap
- $2.07B
- $195.34B
- 1M return
- -14.69%
- -2.57%
- 1Y return
- +59.98%
- -39.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 14
- 11
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLYS
- Mineralys Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Mineralys Therapeutics Inc.
- Mineralys Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
- Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
- Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
- Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Mineralys Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Medical Officer Rodman David Malcom exercised 417 shares at a strike of $15.44 and sold $11,488 worth of shares (417 units at $27.55) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates